Skip to main content

Month: April 2021

Weight loss surgery significantly reduces brain pressure in patients with IIH

Weight loss surgery is more effective than dieting to reduce brain pressure that can cause blindness in patients with a neurological condition, finds a study led by Birmingham Health Partners founder-members the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust (UHB).

Idiopathic Intracranial Hypertension (IIH) is a debilitating condition that raises pressure in the brain and can lead to chronic headaches and even permanent sight loss. The illness, which often leaves patients with a reduced quality of life, predominately affects women aged 25 to 36 and weight gain is a major risk factor of developing IIH and relapses of the disease.

Weight loss has been shown to be an effective treatment, with a reduction in body weight of between three to 15% inducing disease remission. However, maintaining weight loss is notoriously difficult, as most patients regain weight over a two to five year period.

In the first clinical trial of its kind, the research team set out to analyse whether bariatric surgery or a 12-month community weight management intervention (delivered through WW) would be the most effective for reducing brain pressure in women with IIH.

The trial, supported by the National Institute for Health Research (NIHR), involved 66 women with IIH with an average age of 32 years and a body mass index (BMI) of 35 or more. Half underwent bariatric surgery, while the other half took part in WW. Brain pressure was measured by lumbar puncture at the start and after 12 and 24 months.

The results, published today in JAMA Neurology, showed that bariatric surgery was significantly more effective than community weight management, with those having had surgery seeing an average intracranial pressure reduction of 25% after 12 months.

The results also showed that the surgery group lost on average 23Kg, as compared to losing 2kg in the WW group at 12 months. This difference was greater at 24 months with 24% more weight lost in the surgery group as compared to WW. This was because the bariatric surgery group continued to lose more weight over time (28Kg from the start of the study to 2 years), whilst the community weight management group had regained weight lost and, on average, were only 1kg lighter than at the start of the study.

Senior author Alex Sinclair, Professor of Neurology at the University of Birmingham and Neurology lead of the Idiopathic Intracranial Hypertension Service at UHB, said: “A link between weight and IIH has long been observed but, until now, there has been no robust evidence that weight loss can reduce brain pressure.

“We have shown that weight loss achieved through bariatric surgery is significantly more therapeutic than community weight loss management interventions both in the short and longer term to treat IIH brain pressure.

“Whilst we recognise that bariatric surgery may not be an appropriate approach for all patients with IIH and increased weight, it is important to now have the evidence that a surgical approach can lead to significant sustained disease remission.”

First author Dr Susan Mollan, Director of Ophthalmic Research at UHB, added: “We hope that as a consequence of this research, current NHS and NICE guidance can change to include bariatric surgery as a treatment for women with IIH and a BMI greater than 35 when appropriate and in line with the patient’s best interests and wishes.

“Weight stigma is a major barrier to patient care in IIH. We also hope this research will prompt discussion and education around weight management to ensure this sensitive topic is approached with care and dignity.”

Co-author James Mitchell, Lecturer in Neurology at the University of Birmingham, added: “Weight regain is often driven by biology rather than willpower, and obesity is a chronic relapsing disease that requires lifelong treatment. Therefore, it’s essential that patients are given appropriate support to achieve weight loss and further work is done to ensure they have good access to weight management services.”

End the postcode lottery in miscarriage care and treatment, say researchers

Leading experts at BHP founder-member the University of Birmingham and Tommy’s National Centre for Miscarriage Research are calling on the UK government to invest in early pregnancy units and recurrent miscarriage clinics to end the current care and treatment postcode lottery.

The calls come as the team has laid bare the devastating impact of miscarriage and sets out recommendations to improve treatment and care in a series of three articles published today in The Lancet.

Urgent changes should be made to NHS policy, which currently provides exploratory testing for underlying causes of miscarriage for women only after they have experienced three consecutive miscarriages.

The team says many of the risks related to a miscarriage are present even after one or two miscarriages, and appropriate care should be provided to all women who have experienced one or more miscarriages.

Miscarriage care must also go beyond current best practice to include long-term mental health support to those who need it, while high-risk groups should also be offered specialist help from pre-conception and throughout pregnancy, they say.

While the UK provides national statistics for losses such as stillbirth and neonatal death, it does not for miscarriage. The team is calling for the UK – and all countries globally – to routinely publish their national miscarriage statistics to provide a vital benchmark to improve from; accelerate further research; develop public health policy; and ultimately improve care and support for families.

Together, following analysis of systematic reviews; appraisal of existing guidelines; and a UK-wide conference of experts, the researchers have developed recommendations for healthcare practice grouped into three categories: diagnosis of miscarriage, prevention of miscarriage in women with early pregnancy bleeding, and management of miscarriage.

An estimated 23 million miscarriages occur every year worldwide – equating to 44 pregnancy losses each minute. Miscarriage (defined as the loss of a pregnancy before 24 weeks) costs the UK at least £471 million a year due to direct impact on health services and lost productivity. However, scientists expect costs surpass £1 billion per year when factoring in longer-term physical, reproductive and mental health impacts.

Women have a 15% risk of miscarriage, and the team’s review of existing research shows risk factors for miscarriage include older age in both males and females, previous miscarriages, smoking, alcohol, and stress levels.

While the link between age and miscarriage is well established, the review uncovered a significant risk to black women, with 40% higher miscarriage rates in this group than their white counterparts. The researchers say further investigation is needed to understand the reasons for this stark contrast, and they are exploring whether it could be related to other health issues that more commonly affect black women that can complicate pregnancy, such as fibroid conditions and autoimmune disorders.

While some risk factors can be controlled, such as alcohol consumption and smoking, many cannot. Therefore, the researchers say care and support must be targeted at these higher-risk groups in addition to nation-wide changes to ensure quality services are consistently available to all.

The consequences of miscarriage are both physical, such as bleeding or infection, and psychological. The team of Tommy’s and University of Birmingham researchers found profound psychological effects on both parents – miscarriage almost quadrupled the risk of suicide, doubled the risk of depression, and similarly raised the risk of anxiety. Previous studies from another team at Tommy’s National Centre for Miscarriage Research showed that one in five mothers and one in twelve partners experience long-term symptoms of post-traumatic stress after loss.

Senior research author Arri Coomarasamy, Professor of Gynaecology & Reproductive Medicine at the University of Birmingham and Director of Tommy’s National Centre for Miscarriage Research, said: “Despite the many advances in miscarriage research and care, we are really just at the beginning, with many more avenues to investigate – for example, we need to understand why there is a higher rate of miscarriage in black women and why miscarriage is associated with an increased future risk of premature birth.

“We don’t even know exactly how many miscarriages happen in the UK; without this data, the scale of the problem is hidden, and addressing it will not be prioritised.

“As we work to open the ‘black box’ of miscarriage in the hope of unpicking its causes and finding new therapies, the UK must change its approach to miscarriage care, not only to reduce the risk wherever possible but also to better support those who do tragically lose their babies.”

Tommy’s CEO Jane Brewin said: “The variation in quality and availability of miscarriage care across the UK can lead to life-long problems for families already enduring an unbearable experience; it shouldn’t matter who you are or where you live, and you shouldn’t have to endure repeated heart-breaking losses before you get the right help.

“Everyone should be given care and advice after each miscarriage to reduce the chance of it happening again, with specialist support for those most at risk. Mothers’ care must consider their long-term risks, especially in future pregnancies, and both parents must be offered mental health support.

“We know what to do and how to do it – now we need a commitment from the NHS to put the knowledge we have into practice everywhere. With national targets to reduce premature birth and stillbirth, it’s time to prioritise miscarriage too.”

Recommendations outlined in The Lancet papers include:

    • Individualised care according to women’s and their partners’ needs and preferences.
    • Early pregnancy services focused on providing an effective ultrasound service and miscarriage management pathway, including medical management and surgical management.
    • Prescribing vaginal micronized progesterone for pregnant women with the dual risk factors of early pregnancy bleeding and a history of previous miscarriage.
    • Training for clinical nurse specialists and doctors to deliver comprehensive miscarriage care in dedicated early pregnancy units.
    • A defined and universally available minimum set of investigations and treatments to be offered to couples suffering recurrent miscarriages.
    • Screening and care for mental health issues and future obstetric risks incorporated into the care pathway for couples with a history of recurrent miscarriage.
    • Structured care using a ‘graded model’ where women are offered online healthcare advice and support, care in a nurse or midwife-led clinic, and care in a medical consultant-led clinic, according to clinical needs.

To find out more about the research, visit Tommy’s ‘Miscarriage Matters’ campaign, and sign a campaign petition stating mothers should not have to experience three miscarriages before they receive specialist care.

    Birmingham Health Innovation Campus takes another step forward after planning permission granted

    Work is set to begin on the first phase of Birmingham Health Innovation Campus this Summer after planning permission was granted by Birmingham City Council.

    The first phase will see the development of No.1 Birmingham Health Innovation Campus which will offer 133,000 sq ft of lab and office space purposely designed for health innovation and life sciences businesses, with a focus on those working in medtech, precision medicine, biopharma and digital healthcare.

    The building will include the home of the University of Birmingham’s Precision Health Technologies Accelerator (PHTA), providing innovation and incubation spaces for businesses to engage with academics and clinicians, bringing together capabilities in diagnostics, data, clinical trials and medical technologies.

    The Campus positions the West Midlands to capitalise on the UK’s emerging healthtech sector, which attracted £1.12bn in investment in 2020, according to the latest report by Tech Nation, and has already been designated a Life Science Opportunity Zone by the Department for Business, Energy and Industrial Strategy (BEIS). It has also been identified as part of the High Potential Opportunity for Data Driven Healthcare by the Department for International Trade (DIT).

    Companies located at Birmingham Health Innovation Campus will benefit from high quality lab and office space, and access to a fully connected clinical trials translation ecosystem at the region’s NHS Trusts. The Campus will also offer a range of additional facilities including a cafe, indoor and outdoor event space, meeting rooms, cycle storage and car parking.

    The 10-year masterplan will provide up to 657,000 sq ft of state-of-the-art space for the West Midlands’ life sciences sector, supporting the creation of over 10,000 new jobs and contributing £400m of GVA to the regional economy by 2030.

    No.1 Birmingham Health Innovation Campus is being developed in accordance with Bruntwood SciTech’s ongoing commitments to sustainability. Targeting BREEAM ‘Excellent’, the building will incorporate a number of design measures to reduce carbon emissions, mitigate the effects of climate change and protect and enhance the local environment.

    David Hardman, managing director, Bruntwood SciTech – Birmingham, said: “The response since announcing the development of Birmingham Health Innovation Campus, in partnership with the University of Birmingham, has been extremely positive. It’s clear that this is being seen as a real milestone in the evolution of the West Midlands as a health innovation and connected healthcare technologies powerhouse.

    “The region has all the raw ingredients the sector needs – world-class universities, a number of specialist NHS Trusts, quality infrastructure and a growing cluster of SMEs – to support the journey from early R&D to manufacture and market adoption of new health products and services. The Campus will be the epicentre where all these come together and attract further inward investment to ensure the West Midlands has one of the country’s most exciting life sciences propositions for years to come.”

    Professor Tim Jones, University of Birmingham Provost and Vice-Principal, commented: “With the UK beginning a cautious easing of Covid-19 restrictions, this announcement could not be more timely. The speed at which the University and our NHS partners were able to mobilise against the pandemic is indicative of our collaborative and innovative approach to life sciences and medical technologies – an approach which businesses working with us at Birmingham Health Innovation Campus will benefit greatly from.

    “The development is set to play a major role in post-Covid economic recovery, bringing enhanced health, wealth and opportunity to the city and wider West Midlands on a scale rarely witnessed. We are greatly appreciative of the support the Campus has received from the City Council and look forward to progressing with construction.”

    Birmingham Health Innovation Campus is being built in Selly Oak, in the heart of the University of Birmingham’s academic and clinical cluster with the first phase set to complete in 2023.

    The development has received funding from Birmingham City Council to support the enablement of the site. The Precision Health Technologies Accelerator (PHTA) has received £11m from the Greater Birmingham and Solihull Local Enterprise Partnership (GBSLEP) through the Local Fund and the Government’s Getting Building Fund.

    Chair of Greater Birmingham and Solihull Local Enterprise Partnership (GBSLEP), Tim Pile added: “GBSLEP views health and medical technologies as a driver for inclusive economic growth. Our investment of over £11 million into the PHTA reflects our commitment to ensure we create opportunities for businesses to collaborate with industry experts and scale up.

    “Healthcare innovation has been under the spotlight over the last 12 months and Birmingham Health Innovation Campus will undoubtedly help address the health needs that have emerged throughout Covid-19. The PHTA, which we have funded, highlights the way in which GBSLEP works in partnership with universities, businesses and local authorities to target investments in sectors and projects that will elevate our region, create jobs and put us on the global stage as a leader in innovative health and medical technologies.  I look forward to the work commencing on site this summer.”